You are not logged in.
This means
you CAN ONLY VIEW reports that were published prior to Saturday, February 24, 2024.
You
MUST UPGRADE YOUR MEMBERSHIP if you want to see any current reports.
 MIDDAY BREAKOUTS REPORT - MONDAY, APRIL 6TH, 2020
Previous Mid Day Report Next Mid Day Report >>>
|
|
DOW 22152.69 1100.16 (5.23%) | NASDAQ 7749.9 376.82 (5.11%) | S&P 500 2616.29 127.64 (5.13%)
|
Time of Screening :
4/6/2020 12:06:07 PM Report Released :
4/6/2020 12:31:40 PM
Price is:
Above 52W High and Less Than 52W High
but within 15% of the 52 Week High
Volume Is:
At least 45% of 50 Day Average at
the time of the screening.
More details about this report...
At around
mid-way through each trading day we run
a screen against our database of
high-ranked stocks, searching for
possible buy candidates that are trading
at or near their 52-week high on above
average volume. The results of that
screen are split into the two sections
you see below. The first, titled
"TODAY's FEATURED STOCKS" shows stocks
that our experts have recently
identified as among the strongest candidates to
consider. Stocks highlighted in yellow
are the most timely and noteworthy, so
particular attention and prompt action
may be appropriate. The second section,
titled "TODAY's BREAKOUT SCREEN" shows
the remainder of stocks meeting today's
screen parameters. Our experts have
reviewed and included notes on these
stocks as well, but found that they may
not match up as favorably.
|
|
Y - Today's strongest
candidates
highlighted
by our staff
of experts.
|
|
G - Previously featured in
this report as yellow and
now may no longer be buyable
under the guidelines.
|
|
|
|
NONE OF OUR FEATURED STOCKS MET TODAY'S SCREENING CRITERIA FOR VOLUME AND PRICE ACTION.
|
|
 |
Symbol - Exchange - Industry Group
Company Name |
Last |
Chg |
Day
High |
52 WK Hi |
% From Hi |
Volume
% DAV |
DAV |
ABT
- NYSE - DRUGS - Drug Manufacturers - Major
Abbott Laboratories
|
$80.79 |
+1.34
1.69%
|
$81.69
|
$92.45
|
-12.61% |
4,564,532
48.17%
|
9,475,000
|
Most Recent Note for ABT - 4/6/2020 12:07:14 PM
Rebounded to challenge its 200 DMA line ($84) with a gap up and big volume-driven gain on 3/30/20 following approval of a rapid coronavirus test. Reported earnings +17% on +7% sales revenues for the Dec '19 quarter versus the year ago period. Prior quarterly comparisons versus the year ago periods were below the +25% minimum guideline (C criteria).
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
AUDC
- NASDAQ - ELECTRONICS - Scientific & Technical Instrum
Audiocodes Ltd
|
$25.72 |
+0.13
0.49%
|
$26.94
|
$28.73
|
-10.49% |
308,616
60.16%
|
513,000
|
Most Recent Note for AUDC - 4/6/2020 12:09:12 PM
Rebounding impressively after a deep pullback since dropped from the Featured Stocks list on 2/27/20. Did not form a sound base, yet faces little resistance due to overhead supply up to the $28 level. Fundamentals remain strong after it reported earnings +30% on +15% sales revenues for the Dec '19 quarter.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
DOCU
- NASDAQ - Computer Sftwr-Enterprse
Docusign Inc
|
$88.66 |
+9.66
12.23%
|
$89.42
|
$98.38
|
-9.88% |
2,246,757
75.62%
|
2,971,000
|
Most Recent Note for DOCU - 4/6/2020 12:10:37 PM
Consolidating after reaching a new all-time high last week with big volume-driven gains. It did not form a sound base yet rallied impressively after recently finding support at its 200 DMA line ($67). Earnings history included a -67% comparison in the Jul '19 quarter versus the year ago period, but otherwise results have been very strong with solid sales revenues growth.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
DRD
- NYSE - METALS & MINING - Gold
Drdgold Ltd Adr
|
$6.64 |
+0.77
13.12%
|
$6.93
|
$7.79
|
-14.76% |
357,804
125.99%
|
284,000
|
Most Recent Note for DRD - 4/6/2020 12:15:14 PM
Recent quarterly comparisons through Dec '19 showed greatly improved sales revenues and strong earnings increases versus year ago losses. Fundamental concerns remain as when last noted with caution in the 2/07/13 mid-day report - "This low-priced South African company in the Mining - Gold/Silver/Gems group has an erratic earnings history, not a match with the fact-based investment system's guidelines."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
FTNT
- NASDAQ - Computer Sftwr-Security
Fortinet Inc
|
$104.73 |
+3.29
3.24%
|
$105.37
|
$121.82
|
-14.03% |
1,328,976
57.21%
|
2,323,000
|
Most Recent Note for FTNT - 4/6/2020 12:19:59 PM
Rebounding above its 50 DMA line ($104) today, but it faces resistance due to overhead supply up to the $121 level. Rebounded after slumping well below its 200 DMA line ($93.60) and triggering worrisome technical sell signals. Dropped from the Featured Stocks list on 3/09/20, however, fundamentals remain strong.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
INCY
- NASDAQ - DRUGS - Biotechnology
Incyte Corporation
|
$83.28 |
+4.69
5.97%
|
$83.74
|
$96.79
|
-13.96% |
1,205,926
61.59%
|
1,958,000
|
Most Recent Note for INCY - 4/6/2020 12:22:12 PM
Recent quarterly comparisons through Dec '19 have not shown strong and steady earnings increases. Rebounding above its 50 DMA line, it faces some resistance due to overhead supply up to the $96 level
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
LOGI
- NASDAQ - COMPUTER HARDWARE - Computer Peripherals
Logitech Intl Sa
|
$44.58 |
+1.50
3.47%
|
$45.19
|
$48.83
|
-8.71% |
266,082
74.32%
|
358,000
|
Most Recent Note for LOGI - 4/6/2020 12:22:58 PM
Gapped up today. Impressively rebounded above its 50 and 200 DMA lines with recent volume-driven gains. Fundamental concerns remain. Reported earnings +6% on +4% sales revenues for the Dec '19 quarter and prior quarterly comparisons were below the +25% minimum earnings guideline (C criteria). This Switzerland-based Computer - Hardware/Peripherals firm went through a deep V shaped pullback since challenging its all-time high in January after a deep 18-month consolidation.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
OSUR
- NASDAQ - DRUGS - Diagnostic Substances
Orasure Technologies Inc
|
$11.09 |
+0.78
7.59%
|
$11.59
|
$11.77
|
-5.75% |
819,410
98.72%
|
830,000
|
Most Recent Note for OSUR - 4/6/2020 12:23:27 PM
Consolidating after rallying impressively with a spurt of volume-driven gains. Prior mid-day reports noted - "Quarterly and annual earnings history (C and A criteria) is not a match with the fundamental guidelines of the fact-based investment system."
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
QDEL
- NASDAQ - DRUGS - Diagnostic Substances
Quidel Corp
|
$95.52 |
+0.52
0.55%
|
$98.22
|
$106.56
|
-10.36% |
237,987
49.58%
|
480,000
|
Most Recent Note for QDEL - 4/6/2020 12:24:09 PM
Consolidating after spiking to a new all-time high with recent volume-driven gains. This San Diego, CA based maker of rapid diagnostic tests for infectious diseases has earned a high Earnings Per Share rating of 95. Reported earnings +23% on +15% sales revenues for the Dec '19 quarter and prior quarterly earnings comparisons were below the +25% minimum guideline (C criteria). Annual earnings (A criteria) history include a slight downturn in FY '19 following strong earnings growth in FY '17 and '18.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
VIPS
- NYSE - Retail-Internet
Vipshop Holdings Ltd Ads
|
$15.45 |
+1.34
9.46%
|
$15.67
|
$17.85
|
-13.47% |
3,886,790
54.27%
|
7,162,000
|
Most Recent Note for VIPS - 4/6/2020 12:24:30 PM
Reported earnings +116% on +11% sales revenues for the Dec '19 quarter, its 3rd strong quarterly comparison with earnings above the +25% minimum guideline (C criteria). Found prompt support near its 50 DMA line during its consolidation after a big gap up and volume-driven gain on 3/05/20. Faces resistance due to overhead supply up to the $19 level. Apr '15 high was $30, up considerably from its Mar '12 IPO at a split-adjusted $0.70 per share. Completed a Secondary offering on 3/11/14. Downturn in FY '18 is a noted flaw in its annual earnings (A criteria) history.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
VRTX
- NASDAQ - Medical-Biomed/Biotech
Vertex Pharmaceuticals
|
$245.63 |
+7.32
3.07%
|
$255.00
|
$249.85
|
-1.69% |
1,318,154
65.45%
|
2,014,000
|
Most Recent Note for VRTX - 4/6/2020 12:31:35 PM
Hit a new all-time high with today's gap up and volume-driven gain. Recently tested support at its 200 DMA line ($202.67). Reported earnings +31% on +62% sales revenues for the Dec '19 quarter. The Sep '19 quarter was below the +25% minimum earnings guideline (C criteria). Annual earnings (A criteria) has improved greatly following losses in FY '13-15.
|
|
View all notes |
Alert me of new notes |
Company Profile |
SEC |
News |
Chart | C
A N
S L
I M
|
|
|
|
THESE ARE NOT BUY RECOMMENDATIONS!
Comments contained in the body of this report are technical
opinions only. The material herein has been obtained
from sources believed to be reliable and accurate, however,
its accuracy and completeness cannot be guaranteed.
We are not an investment advisor, hence it does
not endorse or recommend any securities or other investments.
Any recommendation contained in this report may not
be suitable for all investors and it is not to be deemed
an offer or solicitation on our part with respect to
the purchase or sale of any securities. All trademarks,
service marks and trade names appearing in this report
are the property of their respective owners, and are
likewise used for identification purposes only.
This report is a service available
only to active Paid Premium Members.
You may opt-out of receiving report notifications
at any time. Questions or comments may be submitted
by writing to FactBasedInvesting.com c/o Premium
Member Services 665 S.E. 10 Street, Suite 201
Deerfield Beach, FL 33441-5634 or by calling 954-785-1121.
We appreciate any feedback
members may wish to send via the inquiry form
here.
|
|
